Payment overview · 2025
General Payments
$288.72
9 reported records · 6 companies
Healthcare provider profile · identity verified
Maria T Batilo, MD
Allopathic & Osteopathic Physicians|Internal Medicine · NORTH FALMOUTH, MA · NPI 1952465866
Verified facts
What the public records show
CMS Open Payments records show Maria T Batilo, MD received $288.72 in general payments during 2025 across 9 reported records.
AstraZeneca Pharmaceuticals LP accounted for 41.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nuedexta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $120.65 | 41.8% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $62.05 | 21.5% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $46.13 | 16.0% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $21.40 | 7.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $19.74 | 6.8% | 1 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $18.75 | 6.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $288.72 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $120.65 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $62.05 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $46.13 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $21.40 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $21.40 | 1 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $18.75 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 254 | 57 |
| Gabapentin | Gabapentin | 205 | 41 |
| Amlodipine Besylate | Amlodipine Besylate | 199 | 41 |
| Atorvastatin Calcium | Atorvastatin Calcium | 191 | 52 |
| Lisinopril | Lisinopril | 185 | 34 |
| Trazodone Hcl | Trazodone Hcl | 184 | 44 |
| Furosemide | Furosemide | 165 | 33 |
| Pantoprazole Sodium | Pantoprazole Sodium | 157 | 29 |
| Eliquis | Apixaban | 141 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 116 | 22 |
| Oxycodone Hcl | Oxycodone Hcl | 116 | 30 |
| Sertraline Hcl | Sertraline Hcl | 111 | 22 |
| Metoprolol Succinate | Metoprolol Succinate | 98 | 24 |
| Potassium Chloride | Potassium Chloride | 86 | 14 |
| Spironolactone | Spironolactone | 84 | 17 |
| Omeprazole | Omeprazole | 78 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 77 | 24 |
| Losartan Potassium | Losartan Potassium | 76 | 22 |
| Mirtazapine | Mirtazapine | 67 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 66 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 61 | suppressed |
| Trulicity | Dulaglutide | 61 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 56 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 53 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 52 | 12 |
| Tramadol Hcl | Tramadol Hcl | 52 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 50 | 11 |
| Prednisone | Prednisone | 50 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 49 | 15 |
| Alprazolam | Alprazolam | 48 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 46 | suppressed |
| Lorazepam | Lorazepam | 45 | 17 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 43 | suppressed |
| Simvastatin | Simvastatin | 43 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 42 | 23 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 41 | suppressed |
| Januvia | Sitagliptin Phosphate | 41 | suppressed |
| Metformin Hcl | Metformin Hcl | 41 | 16 |
| Clozapine | Clozapine | 40 | suppressed |
| Famotidine | Famotidine | 40 | suppressed |
| Finasteride | Finasteride | 40 | suppressed |
| Atenolol | Atenolol | 38 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 38 | 15 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 37 | suppressed |
| Clonazepam | Clonazepam | 37 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 37 | 12 |
| Xifaxan | Rifaximin | 37 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 36 | 26 |
| Montelukast Sodium | Montelukast Sodium | 36 | suppressed |
| Primidone | Primidone | 36 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 35 | suppressed |
| Lamotrigine | Lamotrigine | 33 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 32 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 31 | suppressed |
| Latanoprost | Latanoprost | 30 | suppressed |
| Olanzapine | Olanzapine | 30 | suppressed |
| Topiramate | Topiramate | 28 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 27 | suppressed |
| Digoxin | Digoxin | 27 | suppressed |
| Enulose | Lactulose | 26 | suppressed |
| Lovastatin | Lovastatin | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 26 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 25 | suppressed |
| Entresto | Sacubitril/Valsartan | 25 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 24 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 24 | suppressed |
| Ozempic | Semaglutide | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 13 |
| Cephalexin | Cephalexin | 22 | 18 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 22 | suppressed |
| Jardiance | Empagliflozin | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | 16 |
| Scopolamine | Scopolamine | 21 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 20 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 20 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 18 | suppressed |
| Ezetimibe | Ezetimibe | 18 | suppressed |
| Pregabalin | Pregabalin | 18 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 16 | 16 |
| Baclofen | Baclofen | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 16 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 15 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 15 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 15 | suppressed |
| Procrit | Epoetin Alfa | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Soaanz | Torsemide | 15 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 14 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 13 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Darunavir | Darunavir | 12 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Balsalazide Disodium | Balsalazide Disodium | 11 | suppressed |
| Hydroxyurea | Hydroxyurea | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 11 | suppressed |
| Ritonavir | Ritonavir | 11 | suppressed |
| Valproic Acid | Valproic Acid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $288.72 · 9 records | AstraZeneca Pharmaceuticals LP | BREZTRI, CAPLYTA, CeQur Simplicity, EVENITY, PROLIA, REXULTI | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error